First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration

Autor: Rodon, J. ^{1, ∗}, Prenen, H. ², Sacher, A. ³, Villalona-Calero, M. ⁴, Penel, N. ⁵, El Helali, A. ⁶, Rottey, S. ⁷, Yamamoto, N. ⁸, Ghiringhelli, F. ⁹, Goebeler, M.E. ¹⁰, Doi, T. ¹¹, Postel-Vinay, S. ^{12, 13}, Lin, C.-C. ¹⁴, Liu, C. ¹⁵, Chuang, C.-H. ¹⁵, Keyvanjah, K. ¹⁵, Eggert, T. ¹⁵, O’Neil, B.H. ¹⁶

Publikováno v: In Annals of Oncology December 2024 35(12):1138-1147

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

Autor: Araujo, D., Greystoke, A., Bates, S., Bayle, A., Calvo, E., Castelo-Branco, L., de Bono, J., Drilon, A., Garralda, E., Ivy, P., Kholmanskikh, O., Melero, I., Pentheroudakis, G., Petrie, J., Plummer, R., Ponce, S., Postel-Vinay, S., Siu, L., Spreafico, A., Stathis, A., Steeghs, N., Yap, C., Yap, T.A., Ratain, M., Seymour, L.

Publikováno v: In Annals of Oncology January 2023 34(1):48-60

Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors.

Autor: Kawai-Kawachi A; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Cancer RNA Research Unit, National Cancer Center Research Institute, Tokyo, Japan., Lenormand MM; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Department of Genomes and Genetics, Institut Pasteur, CNRS UMR3525, Paris, France., Astier C; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Université Paris-Saclay, Université Paris-Sud XI, Faculté de Médicine, Le Kremlin Bicêtre, France., Herbel N; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Université Paris-Saclay, Université Paris-Sud XI, Faculté de Médicine, Le Kremlin Bicêtre, France.; Drug Development Department, DITEP, Gustave Roussy, Villejuif, France.; Sarcoma Committee, Gustave Roussy, Villejuif, France.; Viroxis SAS Biotech, Gustave Roussy, Villejuif, France., Cutrona MB; Organoid Core Facility, Gustave Roussy, Villejuif, France., Ngo C; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Sarcoma Committee, Gustave Roussy, Villejuif, France., Garrido M; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France., Eychenne T; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France., Dorvault N; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France., Bordelet L; Experimental and Translational Pathology (PETRA) Platform, AMMICa Unit (CNRS Unit UMS 3655, Inserm Unit US 23), Gustave Roussy, Villejuif, France., Song F; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Bouyakoub R; Organoid Core Facility, Gustave Roussy, Villejuif, France., Loktev A; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Romo-Morales A; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Henon C; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Drug Development Department, DITEP, Gustave Roussy, Villejuif, France.; Sarcoma Committee, Gustave Roussy, Villejuif, France., Colmet-Daage L; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France., Vibert J; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Drug Development Department, DITEP, Gustave Roussy, Villejuif, France.; Sarcoma Committee, Gustave Roussy, Villejuif, France., Drac M; Institute of Molecular Genetics, CNRS Unit UMR 5535, Université de Montpellier, Montpellier, France., Brough R; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Schwob E; Institute of Molecular Genetics, CNRS Unit UMR 5535, Université de Montpellier, Montpellier, France., Martella O; Organoid Core Facility, Gustave Roussy, Villejuif, France., Pinna G; RNA Interference Platform PARi, IRCM/IBFJ/CEA UMRE008, Fontenay-aux-Roses, France., Shipley JM; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Mittnacht S; UCL Cancer Institute, University College London, London, United Kingdom., Zimmermann A; Research Unit Oncology, The Healthcare Business of Merck KGaA, Darmstadt, Germany., Gulati A; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Mir O; Sarcoma Committee, Gustave Roussy, Villejuif, France., Le Cesne A; Sarcoma Committee, Gustave Roussy, Villejuif, France., Faron M; Sarcoma Committee, Gustave Roussy, Villejuif, France., Honoré C; Sarcoma Committee, Gustave Roussy, Villejuif, France., Lord CJ; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Chabanon RM; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Université Paris-Saclay, Université Paris-Sud XI, Faculté de Médicine, Le Kremlin Bicêtre, France.; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Postel-Vinay S; The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.; Université Paris-Saclay, Université Paris-Sud XI, Faculté de Médicine, Le Kremlin Bicêtre, France.; Drug Development Department, DITEP, Gustave Roussy, Villejuif, France.; Sarcoma Committee, Gustave Roussy, Villejuif, France.; UCL Cancer Institute, University College London, London, United Kingdom.

Publikováno v: Cancer research [Cancer Res] 2025 Jan 02; Vol. 85 (1), pp. 154-170.

Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials?

Autor: Mavrikios A; Department of Radiation Oncology, International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France; Sorbonne Université, Faculté de Médecine, Paris, France., Baldini C; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France., Loriot Y; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Université Paris-Saclay, Faculté de Médecine, Kremlin-Bicêtre, France., Hénon C; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France., Marabelle A; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Université Paris-Saclay, Faculté de Médecine, Kremlin-Bicêtre, France., Postel-Vinay S; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Université Paris-Saclay, Faculté de Médecine, Kremlin-Bicêtre, France; Université Paris-Saclay, INSERM U981, Molecular predictors and new targets in oncology, Gustave Roussy, Villejuif, France; University College of London Cancer Institute, London, England., Champiat S; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France., Danlos FX; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France., Quevrin C; Université Paris-Saclay, INSERM U1030, Molecular radiotherapy and therapeutic innovation, Gustave Roussy, Villejuif, France., Lopes E; Université Paris-Saclay, INSERM U1030, Molecular radiotherapy and therapeutic innovation, Gustave Roussy, Villejuif, France., Gazzah A; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France., Bahleda R; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France., Massard C; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Université Paris-Saclay, Faculté de Médecine, Kremlin-Bicêtre, France; Université Paris-Saclay, INSERM U1030, Molecular radiotherapy and therapeutic innovation, Gustave Roussy, Villejuif, France., Deutsch E; Department of Radiation Oncology, International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France; Université Paris-Saclay, Faculté de Médecine, Kremlin-Bicêtre, France; Université Paris-Saclay, INSERM U1030, Molecular radiotherapy and therapeutic innovation, Gustave Roussy, Villejuif, France., Levy A; Department of Radiation Oncology, International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France; Université Paris-Saclay, Faculté de Médecine, Kremlin-Bicêtre, France; Université Paris-Saclay, INSERM U1030, Molecular radiotherapy and therapeutic innovation, Gustave Roussy, Villejuif, France. Electronic address: antonin.levy@gustaveroussy.fr.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2024 Dec 01; Vol. 120 (5), pp. 1245-1256. Date of Electronic Publication: 2024 Aug 10.

Arterial hypertension associated with PARPi: A meta-analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study.

Autor: Blaize C; Department of Pharmacology, Caen-Normandy University Hospital, Caen, France., Surtouque E; Department of Pharmacology, Caen-Normandy University Hospital, Caen, France., Font J; Normandie Univ, UNICAEN, INSERM U1086 'Interdisciplinary Research Unit for Cancers Prevention and Treatment' (ANTICIPE), Caen, France.; Department of Cardiology, Caen-Normandy University Hospital, Caen, France., Dolladille C; Normandie Univ, UNICAEN, INSERM U1086 'Interdisciplinary Research Unit for Cancers Prevention and Treatment' (ANTICIPE), Caen, France.; PICARO Cardio-Oncology Program, Department of Pharmacology, Caen-Normandy University Hospital, Caen, France., Postel-Vinay S; European Research Council (ERC) StG Team, Inserm Unit U981, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.; Faculté de Médicine, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France., Da Silva A; Department of Pharmacology, Caen-Normandy University Hospital, Caen, France.; Department of medical oncology, Caen-Normandy University Hospital, Caen, France., Alexandre J; Normandie Univ, UNICAEN, INSERM U1086 'Interdisciplinary Research Unit for Cancers Prevention and Treatment' (ANTICIPE), Caen, France.; PICARO Cardio-Oncology Program, Department of Pharmacology, Caen-Normandy University Hospital, Caen, France., Morice PM; Department of Pharmacology, Caen-Normandy University Hospital, Caen, France.; Normandie Univ, UNICAEN, INSERM U1086 'Interdisciplinary Research Unit for Cancers Prevention and Treatment' (ANTICIPE), Caen, France.

Publikováno v: Fundamental & clinical pharmacology [Fundam Clin Pharmacol] 2024 Aug; Vol. 38 (4), pp. 610-629. Date of Electronic Publication: 2024 Jan 25.